Lux Biosciences completes enrollment in Phase III cornea transplantation study
Lux Biosciences, a biotechnology company, has completed enrollment in its Phase III Lucida clinical trial program for Lumitect. The Lucida clinical trial program is investigating the one-year use
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.